Literature DB >> 10782833

Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study.

Y Zhang1, M T Hannan, C E Chaisson, T E McAlindon, S R Evans, P Aliabadi, D Levy, D T Felson.   

Abstract

OBJECTIVE: To examine the relations of bone mineral density (BMD) and change in BMD to risk of incident and progressive radiographic knee osteoarthritis (OA) in a longitudinal cohort study.
METHODS: Female participants aged 63 to 91 years (mean age 71) in the Framingham Study received anteroposterior weight bearing knee radiographs at biennial examinations 18 (1983-85) and 22 (1992-93). Knee radiographs were given scores for global severity of OA (Kellgren-Lawrence scale: range 0 to 4) and for the presence of osteophytes and joint space narrowing (range 0 to 3). Femoral neck BMD was assessed using dual photon absorptiometry at examination 20 and dual x-ray absorptiometry at examination 22. We examined the relations of BMD at examination 20 and its change between examination 20 and examination 22 to incident and progressive knee OA, as well as to worsening of individual radiographic features adjusting for age, body mass index, and other potential confounding factors.
RESULTS: In total, 473 women (ages 63 to 91 yrs) had complete assessments. Over 8 years of followup, risk of incident radiographic knee OA increased from 5.6% among women in the lowest age-specific quartile of BMD to 14.2, 10.3, and 11.8% among women in the 2nd, 3rd, and highest quartiles, respectively. Multivariate adjusted OR of incident OA for each increase quartile of BMD were 1.0, 2.5, 2.0, and 2.3, respectively (p for trend = 0.222). This was mainly reflected in an increased risk of osteophyte development. However, risk of progressive OA decreased from 34.4 to 22.0, 20.3, and 18.9% as BMD increased. Compared to those in the lowest quartile of BMD, adjusted OR for progressive disease were 0.3, 0.2, and 0.1 among women in the 2nd, 3rd, and highest quartiles (p for trend <0.001), respectively, mainly due to its effect on lowering the risk of joint space loss. Compared to those who lost BMD >0.04 g/cm2 over the followup period, women who gained BMD were at increased risk of incident but at a significantly decreased risk of progressive knee OA. BMD change was not associated with osteophyte development, but gain in BMD lowered the risk of joint space loss.
CONCLUSION: High BMD and BMD gain decreased the risk of progression of radiographic knee OA, but may be associated with an increased risk of incident knee OA. The protective effect was mainly through its influence on reducing the risk of joint space loss. Our results offer insights into how bone may affect the course of the most common joint disease, and thus may have potential therapeutic implications.

Entities:  

Mesh:

Year:  2000        PMID: 10782833

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  73 in total

1.  Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.

Authors:  P Garnero; M Piperno; E Gineyts; S Christgau; P D Delmas; E Vignon
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  Selection bias in rheumatic disease research.

Authors:  Hyon K Choi; Uyen-Sa Nguyen; Jingbo Niu; Goodarz Danaei; Yuqing Zhang
Journal:  Nat Rev Rheumatol       Date:  2014-04-01       Impact factor: 20.543

3.  Uncovering the "skeleton in the closet": the issue of bone and joint disorders in the Maldives and the opportunities for primary prevention and health promotion.

Authors:  Angela Mary Jackson
Journal:  J Prim Prev       Date:  2006-06-08

4.  C-28/I2 and T/C-28a2 chondrocytes as well as human primary articular chondrocytes express sex hormone and insulin receptors--Useful cells in study of cartilage metabolism.

Authors:  Horst Claassen; Martin Schicht; Jörg Brandt; Katharina Reuse; Ricarda Schädlich; Mary B Goldring; Saskia Sabrina Guddat; Annett Thate; Friedrich Paulsen
Journal:  Ann Anat       Date:  2010-10-25       Impact factor: 2.698

5.  Quadriceps weakness predicts risk for knee joint space narrowing in women in the MOST cohort.

Authors:  N A Segal; N A Glass; J Torner; M Yang; D T Felson; L Sharma; M Nevitt; C E Lewis
Journal:  Osteoarthritis Cartilage       Date:  2010-02-11       Impact factor: 6.576

6.  High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: the MOST study.

Authors:  M C Nevitt; Y Zhang; M K Javaid; T Neogi; J R Curtis; J Niu; C E McCulloch; N A Segal; D T Felson
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

7.  Relationship of bone mineral density to progression of knee osteoarthritis.

Authors:  Ji Y Lee; William F Harvey; Lori L Price; Jessica K Paulus; Bess Dawson-Hughes; Timothy E McAlindon
Journal:  Arthritis Rheum       Date:  2013-06

8.  Reduced Osteoarthritis Severity in Aged Mice With Deletion of Macrophage Migration Inhibitory Factor.

Authors:  Meredith A Rowe; Lindsey R Harper; Margaret A McNulty; Anthony G Lau; Cathy S Carlson; Lin Leng; Richard J Bucala; Richard A Miller; Richard F Loeser
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

9.  Epidemiology of lumbar osteoporosis and osteoarthritis and their causal relationship--is osteoarthritis a predictor for osteoporosis or vice versa?: the Miyama study.

Authors:  N Yoshimura; S Muraki; H Oka; A Mabuchi; H Kinoshita; M Yosihda; H Kawaguchi; K Nakamura; T Akune
Journal:  Osteoporos Int       Date:  2008-11-07       Impact factor: 4.507

10.  The prevalence of symptomatic knee and distal interphalangeal joint osteoarthritis in the urban population of Antalya, Turkey.

Authors:  C Kaçar; E Gilgil; S Urhan; V Arikan; U Dündar; M C Oksüz; G Sünbüloglu; C Yildirim; I Tekeoglu; B Bütün; A Apaydin; T Tuncer
Journal:  Rheumatol Int       Date:  2003-12-06       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.